Future Antidyslipidemic Blockbuster Drugs Nearing End of Development Phase with 18% of the Cariovascular Market: companiesandmarkets.com

  • Antidyslipidemic drugs occupied 18% of the cardiovascular market segment in 2010.
  • EU approval likely for BMS/Pfizer's apixaban
  • Collaborations expected between industry participants and governments/regulatory bodies

LONDON--()--The term cardiovascular disease incorporates several serious illnesses, including arteriosclerosis/atherosclerosis; thrombosis; dyslipidemia; cardiac arrhythmias; myocardial infarction (MI); acute coronary syndrome (ACS); congestive heart failure (CHF); coronary artery disease (CAD); peripheral artery disease (PAD); pulmonary hypertension; angina pectoris and stroke. Dyslipidemia was the indication with the highest reported prevalence in 2010 with an estimated 336 million cases in the seven major markets according to a new report available from companiesandmarkets.com

The Cardiovascular Market Outlook to 2016

http://www.companiesandmarkets.com/Market-Report/the-cardiovascular-market-outlook-to-2016-619580.asp?prk=7c4ed5b510c1ffe12b50d9829eddaba2

The next few years will see the expiration of many blockbuster cardiovascular treatments, allowing for an influx of generic manufacturers to erode the market share of key players. Pharmaceutical companies are focusing on in-licensing and R&D activities in a bid to develop new products which may help to stem the losses after the patents expire.

In 2010, the cardiovascular condition with the highest reported number of incidences was dyslipidemia, which saw over 336 million diagnoses. The same year saw antidyslipidemic drugs take an 18% market share. This cardiovascular disease segment has already seen the entry of generic versions of Pfizer’s renowned Lipitor, although a new CETP inhibitor by Roche – Dalcetrapi, thought to be a future blockbuster – may be able to alleviate the impact of generic drugs on the cardiovascular market.

The antithrombotics segment of the cardiovascular market reported a market share of 11%, and is expected to expand over the reporting period as a result of recent product approvals (e.g. Pradaxa and Xarelto), and the US launch of a drug called apixaban, created by Pfizer and BMS.

The 160 page report on the cardiovascular market was released in June 2011, and provides forecast data to 2016, allowing the reader to understand the structure of the marketplace. The current portfolio, product pipelines and business strategies of the following key players are examined in detail: Pfizer; Sanofi; AstraZeneca; Novartis; Bristol-Myers Squibb (BMS) and Merck.

Report Details:

http://www.companiesandmarkets.com/Market-Report/the-cardiovascular-market-outlook-to-2016-619580.asp?prk=7c4ed5b510c1ffe12b50d9829eddaba2

Contacts

Companies & Markets
Mike King
Press Office
enquiries@companiesandmarkets.com
London (UK): +44 (0) 203 086 8600

Release Summary

In 2010, the cardiovascular condition with the highest reported number of incidences was dyslipidemia, which saw over 336 million diagnoses.

Contacts

Companies & Markets
Mike King
Press Office
enquiries@companiesandmarkets.com
London (UK): +44 (0) 203 086 8600